首页 工具
登录
购物车
ADH-1 trifluoroacetate

ADH-1 trifluoroacetate

产品编号 T1608   CAS 1135237-88-5
别名: Exherin trifluoroacetate

ADH-1 trifluoroacetate (Exherin trifluoroacetate) 是一种选择性的、竞争性N-钙粘蛋白拮抗剂,具有潜在抗肿瘤和抗血管生成作用。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
ADH-1 trifluoroacetate Chemical Structure
ADH-1 trifluoroacetate, CAS 1135237-88-5
规格 价格/CNY 货期 数量
1 mg ¥ 369 现货
5 mg ¥ 869 现货
10 mg ¥ 1,390 现货
25 mg ¥ 2,520 现货
50 mg ¥ 3,730 现货
100 mg ¥ 5,360 现货
1 mL * 10 mM (in DMSO) ¥ 1,370 现货
其他形式的 ADH-1 trifluoroacetate:
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
产品目录号及名称: ADH-1 trifluoroacetate (T1608)
点击图片重新获取验证码
选择批次  
纯度: 99.17%
纯度: 98%
纯度: 98%
纯度: 98%
纯度: 96.64%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 ADH-1 trifluoroacetate (Exherin trifluoroacetate) is a cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis.
体外活性 In pancreatic cancer cells, Exherin (0.2 mg/mL) blocks collagen I-mediated changes and is highly potent at preventing cell motility induced by expression of N-cadherin. Exherin (0-1.0 mg/mL) dose-dependently induces apoptosis in a N-cadherin-dependent manner.
体内活性 In a mouse model for pancreatic cancer, Exherin (50 mg/kg) markedly inhibits tumor growth and metastasis [1]. In a rat aortic ring assay or antitumor potential in a PC3 subcutaneous xenograft tumor model, Exherin does not display either antiangiogenic activity [2]. The augmentation of melanoma tumor growth mediated by Exherin is not altered by regionally infused temozolomide. In A375, but not DM443 xenografts, Exherin can increase phosphorylation of AKT at serine 473. Exherin slightly diminishes N-cadherin expression in both xenografts[3].
动物实验 Exherin is prepared in PBS.Animals are anesthetized, and 40 μL of a single cell suspension containing 50,000 cells is injected into the pancreas. Mice are randomized into treatment groups 10 days after surgery. For treatment, mice are injected intraperitoneally once per day with Exherin at 50 mg/kg in 100 μL PBS (×1 per day, ×5 per week for 4 weeks). For in vivo bioluminescence, D-Luciferin is administered by intraperitoneal injection. Data are acquired 20 min after injection using the IVIS system. Tumor growth is monitored every 10 days from day 10 to day 50 after surgery. Luciferase activity is quantified using the IVIS system. Two months after surgery, the mice are killed, and the pancreas, liver, lung, and disseminated nodules are harvested, fixed in 10% buffered formalin, and embedded in paraffin. Serial 5-μM sections are cut, mounted on slides, and stained with H&E using standard procedures.
别名 Exherin trifluoroacetate
分子量 684.71
分子式 C24H35F3N8O8S2
CAS No. 1135237-88-5

存储

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 43 mg/mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7. 2. Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8. 3. Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77.
MF-438 Mycophenolic acid NCT-501 CM037 SCD1 inhibitor-4 Citric acid trilithium salt tetrahydrate (E/Z)-Teriflunomide WIN 18446

相关化合物库

该产品包含在如下化合物库中:
抗癌药物库 抑制剂库 药物功能重定位化合物库 抗癌活性化合物库 抗癌临床化合物库 共价抑制剂库 经典已知活性库 已知活性化合物库 含氟化合物库 抗代谢疾病化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

ADH-1 trifluoroacetate 1135237-88-5 Metabolism Dehydrogenase Exherin trifluoroacetate ADH 1 ADH1 trifluoroacetate Inhibitor Exherin Trifluoroacetate ADH1 ADH-1 Trifluoroacetate ADH-1 ADH 1 Trifluoroacetate inhibit ADH 1 trifluoroacetate ADH1 Trifluoroacetate inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼